MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-30-2025
AtriCure Net Debt 2011-2025 | ATRC
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt AtriCure
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -59.2 M | -22.3 M | -118 K | 16.9 M | 11.5 M | 33.4 M | 8.06 M | 2.85 M | 1.37 M | -9.6 M | -24.3 M | -8.44 M | 683 K | -3.29 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.4 M | -59.2 M | -3.75 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical instruments industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
11.5 B | $ 19.11 | 0.95 % | $ 9.75 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
17.1 B | $ 196.12 | 0.23 % | $ 56.4 B | USA |
 |
Luminex Corporation
LMNX
|
-106 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
-517 K | - | -9.52 % | $ 20.6 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-5.61 M | $ 5.47 | 3.01 % | $ 110 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
-12.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
781 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
66.8 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
1.58 B | - | -0.05 % | $ 10.3 B | USA |
 |
Harvard Bioscience
HBIO
|
27.8 M | $ 0.73 | 0.64 % | $ 31 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
-411 M | - | -0.02 % | $ 16.3 B | USA |
 |
iRhythm Technologies
IRTC
|
-329 M | $ 175.8 | -1.49 % | $ 5.48 B | USA |
 |
ICU Medical
ICUI
|
1.24 B | $ 146.98 | -0.35 % | $ 3.58 B | USA |
 |
Alcon
ALC
|
2.46 B | $ 80.17 | 0.06 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
-10.8 M | $ 6.48 | -0.61 % | $ 295 M | USA |
 |
Atrion Corporation
ATRI
|
-45 M | - | - | $ 810 M | USA |
 |
LeMaitre Vascular
LMAT
|
145 M | $ 84.34 | 0.44 % | $ 1.89 B | USA |
 |
electroCore
ECOR
|
-9.7 M | $ 4.86 | 1.25 % | $ 26.8 K | USA |
 |
AngioDynamics
ANGO
|
-48.3 M | $ 13.16 | - | $ 538 M | USA |
 |
Merit Medical Systems
MMSI
|
363 M | $ 87.39 | -0.27 % | $ 5.09 B | USA |
 |
The Cooper Companies
COO
|
2.38 B | $ 82.57 | -0.37 % | $ 16.4 B | USA |
 |
Glaukos Corporation
GKOS
|
-21.6 M | $ 116.64 | 0.4 % | $ 5.65 B | USA |
 |
Masimo Corporation
MASI
|
572 M | $ 133.28 | -0.44 % | $ 7.1 B | USA |
 |
Haemonetics Corporation
HAE
|
623 M | $ 80.01 | -0.44 % | $ 4.03 B | USA |
 |
InfuSystem Holdings
INFU
|
33.3 M | $ 9.11 | 0.77 % | $ 188 M | USA |
 |
Isoray
ISR
|
-58.9 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
-1.88 B | $ 577.15 | -0.03 % | $ 205 B | USA |
 |
OraSure Technologies
OSUR
|
-266 M | $ 2.43 | 2.53 % | $ 181 M | USA |
 |
Microbot Medical
MBOT
|
-2.24 M | $ 2.18 | - | $ 22.2 M |  Israel |
 |
ResMed
RMD
|
513 M | $ 244.44 | -0.07 % | $ 35.7 B | USA |
 |
Milestone Scientific
MLSS
|
-3.09 M | $ 0.29 | -0.48 % | $ 23.1 M | USA |
 |
Nephros
NEPH
|
-2.48 M | $ 5.23 | 12.23 % | $ 54.3 M | USA |
 |
NeuroMetrix
NURO
|
-1.49 M | - | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
244 M | $ 22.0 | 0.59 % | $ 3.79 B | USA |
 |
STAAR Surgical Company
STAA
|
-105 M | $ 23.63 | -1.25 % | $ 1.16 B | USA |
 |
STERIS plc
STE
|
1.78 B | $ 255.68 | 0.11 % | $ 25.2 B | USA |
 |
Stereotaxis
STXS
|
-14.3 M | $ 2.43 | -0.82 % | $ 196 M | USA |
 |
Pro-Dex
PDEX
|
15 M | $ 40.4 | -2.38 % | $ 133 M | USA |
 |
Pulse Biosciences
PLSE
|
-35.2 M | $ 14.86 | 1.92 % | $ 714 M | USA |
 |
Predictive Oncology
POAI
|
1.4 M | - | - | $ 32.4 M | USA |
 |
Utah Medical Products
UTMD
|
-60.6 M | $ 56.29 | -1.14 % | $ 204 M | USA |
 |
Repligen Corporation
RGEN
|
-236 M | $ 165.66 | -0.42 % | $ 9.23 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.36 B | $ 11.22 | 1.26 % | $ 2.28 B | USA |
 |
BioLife Solutions
BLFS
|
-88.9 M | $ 25.41 | -0.2 % | $ 1.17 B | USA |
 |
Retractable Technologies
RVP
|
-3 M | $ 0.82 | 0.01 % | $ 24.5 M | USA |
 |
Teleflex Incorporated
TFX
|
1.37 B | $ 122.33 | 0.03 % | $ 5.73 B | USA |
 |
West Pharmaceutical Services
WST
|
-264 M | $ 276.66 | -0.3 % | $ 20.2 B | USA |